Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV

Vaccine

Volumn 26, Issue 15, 2008, Pages 1887-1892

  Lee, Lucy F ^a   Lupiani, Blanca ^b   Silva, Robert F ^a   Kung, Hsing Jien ^c   Reddy, Sanjay M ^b  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Marek's disease virus; Meq oncogene; Recombinant MDV; Vaccine

Indexed keywords

LEUCINE ZIPPER PROTEIN; MAREK DISEASE VACCINE; PROTEIN MEQ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHICKEN; CONTROLLED STUDY; CYTOSOL; EPITHELIUM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID ORGAN; MALE; MARDIVIRUS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRULENCE; VIRUS CHARACTERIZATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CHICKENS; FEMALE; MALE; MARDIVIRUS; MAREK DISEASE; MAREK DISEASE VACCINES; ONCOGENE PROTEINS, VIRAL; POULTRY DISEASES; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VIREMIA;

EID: 40849120430     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.046     Document Type: Article

References (37)

1. Nair V. Successful control of Marek's disease by vaccination. Dev Biol 119 (2004) 147-154
2. Bublot M., and Sharma J. Vaccination against Marek's diseases. In: Davidson F., and Nair V. (Eds). Marek's disease an evolving problem (2004), Elsevier Academic Press, London 168-185
3. Churchill A.E., Chubb R.C., and Baxendale W. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture. J Gen Virol 4 June (4) (1969) 557-564
4. Churchill A.E., Payne L.N., and Chubb R.C. Immunization against Marek's disease using a live attenuated virus. Nature 221 February 22 (5182) (1969) 744-747
5. Okazaki W., Purchase H.G., and Burmester B.R. Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis 14 May (2) (1970) 413-429
6. Witter R.L., Nazerian K., Purchase H.G., and Burgoyne G.H. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus. Am J Vet Res 31 March (3) (1970) 525-538
7. Schat K.A., Calnek B.W., and Fabricant J. Characterization of two highly oncogenic strains of Marek's disease virus. Avian Pathol 11 (1982) 593-605
8. Witter R.L., Silva R.F., and Lee L.F. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: selected biological and molecular characteristics. Avian Dis 31 October-December (4) (1987) 829-840
9. Witter R.L., and Lee L.F. Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies. Avian Pathol 13 (1984) 75-92
10. Witter R.L. Increased virulence of Marek's disease virus field isolates. Avian Dis 41 January-March (1) (1997) 149-163
11. Witter R.L. Safety and comparative efficacy of the CVI988/Rispens vaccine strain. Proceedings of the 4th international symposium on Marek's disease, 19th World Poultry Congress. World Poultry Science Association, Amsterdam, The Netherlands (1992) 315-319
12. Rispens B.H., van Vloten H., Mastenbroek N., Maas J.L., and Schat K.A. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis 16 April (1) (1972) 126-138
13. Rispens B.H., van Vloten H., Mastenbroek N., Maas H.J., and Schat K.A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis 16 April (1) (1972) 108-125
14. Kreager K. Chicken industry strategies for control of tumor virus infections. Poult Sci 77 August (8) (1998) 1213-1216
15. Witter R.L., and Kreager K.S. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease. Avian Dis 48 December (4) (2004) 768-782
16. Yoshida S., Lee L.F., Yanagida N., and Nazerian K. The glycoprotein B genes of Marek's disease virus serotypes 2 and 3: identification and expression by recombinant fowlpox viruses. Virology 200 May (2) (1994) 484-493
17. Nazerian K., Witter R.L., Lee L.F., and Yanagida N. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus. Avian Dis 40 April-June (2) (1996) 368-376
18. Lee L.E., Witter R.L., Reddy S.M., Wu P., Yanagida N., and Yoshida S. Protection and synergism by recombinant fowl pox vaccines expressing multiple genes from Marek's disease virus. Avian Dis 47 July-September (3) (2003) 549-558
19. Lee L.F., Bacon L.D., Yoshida S., Yanagida N., Zhang H.M., and Witter R.L. The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype. Avian Dis 48 January-March (1) (2004) 129-137
20. Tischer B.K., Schumacher D., Beer M., Beyer J., Teifke J.P., Osterrieder K., et al. A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens. J Gen Virol 83 October (Pt 10) (2002) 2367-2376
21. Trapp S., Parcells M.S., Kamil J.P., Schumacher D., Tischer B.K., Kumar P.M., et al. A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis. J Exp Med 203 May (5) (2006) 1307-1317
22. Fragnet L., Blasco M.A., Klapper W., and Rasschaert D. The RNA subunit of telomerase is encoded by Marek's disease virus. J Virol 77 May (10) (2003) 5985-5996
23. Cortes P.L., and Cardona C.J. Pathogenesis of a Marek's disease virus mutant lacking vIL-8 in resistant and susceptible chickens. Avian Dis 48 January-March (1) (2004) 50-60
24. Parcells M.S., Lin S.F., Dienglewicz R.L., Majerciak V., Robinson D.R., Chen H.C., et al. Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV. J Virol 75 June (11) (2001) 5159-5173
25. Cui X., Lee L.F., Hunt H.D., Reed W.M., Lupiani B., and Reddy S.M. A Marek's disease virus vIL-8 deletion mutant has attenuated virulence and confers protection against challenge with a very virulent plus strain. Avian Dis 49 June (2) (2005) 199-206
26. Cui X., Lee L.F., Reed W.M., Kung H.J., and Reddy S.M. Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency. J Virol 78 May (9) (2004) 4753-4760
27. Lupiani B., Lee L.F., Cui X., Gimeno I., Anderson A., Morgan R.W., et al. Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc Natl Acad Sci USA 101 August (32) (2004) 11815-11820
28. Brown A.C., Baigent S.J., Smith L.P., Chattoo J.P., Petherbridge L.J., Hawes P., et al. Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus. Proc Natl Acad Sci USA 103 February (6) (2006) 1687-1692
29. Cui Z.Z., Lee L.F., Liu J.L., and Kung H.J. Structural analysis and transcriptional mapping of the Marek's disease virus gene encoding pp38, an antigen associated with transformed cells. J Virol 65 December (12) (1991) 6509-6515
30. Reddy S.M., Lupiani B., Gimeno I.M., Silva R.F., Lee L.F., and Witter R.L. Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function. Proc Natl Acad Sci USA 99 May (10) (2002) 7054-7059
31. Jarosinski K.W., Osterrieder N., Nair V.K., and Schat K.A. Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a. J Virol 79 September (18) (2005) 11647-11659
32. Jones D., Lee L., Liu J.L., Kung H.J., and Tillotson J.K. Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. Proc Natl Acad Sci USA 89 May (9) (1992) 4042-4046
33. Witter R.L. Induction of strong protection by vaccination with partially attenuated serotype 1 Marek's disease viruses. Avian Dis 46 October-December (4) (2002) 925-937
34. Witter R.L., Lee L.F., and Fadly A.M. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian Dis 39 April-June (2) (1995) 269-284
35. de Boer G.F., Groenendal J.E., Boerrigter H.M., Kok G.L., and Pol J.M. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains. Avian Dis 30 April-June (2) (1986) 276-283
36. Pol J.M., Kok G.L., Oei H.L., and de Boer G.F. Pathogenicity studies with plaque-purified preparations of Marek's disease virus strain CVI-988. Avian Dis 30 April-June (2) (1986) 271-275
37. Jarosinski K., Kattenhorn L., Kaufer B., Ploegh H., and Osterrieder N. A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation. Proc Natl Acad Sci USA 104 December (50) (2007) 20025-20030